Are you tired of out of box, one size fits all solutions to quantitating your biologic drug? - AIT BioscienceAIT Bioscience

Are you tired of out of box, one size fits all solutions to quantitating your biologic drug?

We’ll meet you where you are

 

with our customized approach

 

Are you tired of out of box, one size fits all solutions to quantitating your biologic drug?

 

AIT Bioscience knows that when it comes to your biologic drug, there is no one size fits all approach. Thanks to our experienced scientific team and our ability to flex seamlessly across multiple platforms (LC/MS/MS, LC/HRMS, Biotek, MSD); we can create customized assays that meet the needs of your drug and your therapeutic indication.

 

 

Our assays grow with you

 

As your drug development needs change, we modify our assays transform to help you accelerate your portfolio from discovery PK assessments, to GLP toxicology support or clinical PK/ADA assessments. By integrating science with technology, we efficiently support your PK, ADA/NAB, and/or biomarker assessments. We have a breadth of experience supporting many biotherapeutics including:

 

  • Peptides
  • Insulin and glucagon derivatives
  • Conjugated peptides
  • Fusion proteins – view our case study
  • Recombinant proteins
  • Monoclonal antibodies
  • Multi-domain antibodies
  • Antibody-Drug Conjugates (ADCs) – view our case study
  • Gene Therapy vectors and products

 

No matter where you are in the drug development process, we can support your needs. Learn more about our LBA capabilities and contact Mark Cameron, Vice President of Scientific Services, Ligand Binding Assays to see how we can meet you where you are.

Share this with your colleagues.

Categories: Ligand Binding Assays (LBA).


Tags: , , , ,